Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
June 01, 2020 07:00 ET | Source: Oxford BioMedica plc

Dr Roch Doliveux appointed Non-Executive Chairman

Oxford Biomedica Appoints Dr. Roch Doliveux as Non-Executive Chairman Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell...
May 28, 2020 07:38 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
May 06, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica plc Preliminary results for the year ended 31 December 2019

Oxford Biomedica plcPreliminary results for the year ended 31 December 2019 Building the Group for future growth Oxford, UK – 6 May 2020: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a...
September 04, 2019 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Interim Results

OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell...
March 26, 2019 08:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia

Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene...
March 14, 2019 08:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica plc: Preliminary results for the year ended 31 December 2018

Oxford Biomedica plcPreliminary results for the year ended 31 December 2018 Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE: OXB),...
October 25, 2018 07:00 ET | Source: Oxford BioMedica plc

Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease

Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease Oxford, UK – 25 October 2018: Oxford BioMedica...
September 13, 2018 07:00 ET | Source: Oxford BioMedica plc

Oxford BioMedica announces further capacity expansion with new facility

Oxford BioMedica announces further capacity expansion with new facility Lentiviral vector bioprocessing market expected to grow to $800m by 2026Oxford BioMedica adds fourth facility in Oxford...
September 13, 2018 07:00 ET | Source: Oxford BioMedica plc

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018

OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018 Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell...